--- title: "Preferred Stock, Definition | MedTech Terms" description: "Class of equity with rights superior to common stock. Plain-English Investment & Finance definition for MedTech teams, with examples and related terms." lang: en json-ld: | { "@context": "https://schema.org", "@graph": [ { "@type": "DefinedTerm", "@id": "https://medtechterms.com/terms/preferred-stock#term", "name": "Preferred Stock", "description": "Preferred stock is the security class issued to venture investors. It carries a liquidation preference, anti-dilution protection, dividend rights, protective provisions (veto rights over key actions), and often board representation - rights not held by common stockholders.", "url": "https://medtechterms.com/terms/preferred-stock", "termCode": "preferred-stock", "inDefinedTermSet": { "@type": "DefinedTermSet", "name": "MedTech Terms", "url": "https://medtechterms.com/terms" } }, { "@type": "Article", "@id": "https://medtechterms.com/terms/preferred-stock#article", "headline": "Preferred Stock", "description": "Class of equity with rights superior to common stock.", "url": "https://medtechterms.com/terms/preferred-stock", "mainEntityOfPage": { "@type": "WebPage", "@id": "https://medtechterms.com/terms/preferred-stock" }, "about": { "@id": "https://medtechterms.com/terms/preferred-stock#term" }, "articleSection": "Investment & Finance", "inLanguage": "en", "keywords": "Preferred Stock, Investment & Finance, medical device, MedTech", "author": { "@type": "Person", "name": "Christian Espinosa", "jobTitle": "Founder, Blue Goat Cyber", "url": "https://bluegoatcyber.com" }, "publisher": { "@type": "Organization", "name": "MedTech Terms", "url": "https://medtechterms.com" }, "isPartOf": { "@type": "WebSite", "name": "MedTech Terms", "url": "https://medtechterms.com" }, "datePublished": "2026-05-05", "dateModified": "2026-05-05", "citation": [ { "@type": "CreativeWork", "name": "NVCA model docs", "url": "https://nvca.org/model-legal-documents/", "publisher": { "@type": "Organization", "name": "NVCA" } }, { "@type": "CreativeWork", "name": "Silicon Valley Bank - Healthcare Reports", "url": "https://www.svb.com/trends-insights/", "publisher": { "@type": "Organization", "name": "SVB" } }, { "@type": "CreativeWork", "name": "PitchBook - MedTech Coverage", "url": "https://pitchbook.com/news/articles/topic/healthtech", "publisher": { "@type": "Organization", "name": "PitchBook" } } ], "mentions": [ { "@type": "DefinedTerm", "@id": "https://medtechterms.com/terms/liquidation-preference#term", "name": "Liquidation Preference", "url": "https://medtechterms.com/terms/liquidation-preference" } ] }, { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://medtechterms.com/" }, { "@type": "ListItem", "position": 2, "name": "Terms", "item": "https://medtechterms.com/terms" }, { "@type": "ListItem", "position": 3, "name": "Investment & Finance", "item": "https://medtechterms.com/terms?cat=Investment%20%26%20Finance" }, { "@type": "ListItem", "position": 4, "name": "Preferred Stock", "item": "https://medtechterms.com/terms/preferred-stock" } ] }, { "@type": "FAQPage", "@id": "https://medtechterms.com/terms/preferred-stock#faq", "mainEntity": [ { "@type": "Question", "name": "How does preferred stock impact a MedTech company's regulatory obligations?", "acceptedAnswer": { "@type": "Answer", "text": "Preferred stock provisions, particularly those granting control or veto rights, can influence a company's decision-making processes, which in turn affect its ability to meet regulatory deadlines, implement corrective actions, or respond to regulatory inquiries. It indirectly affects the regulatory obligations of a MedTech company as the distribution and terms of preferred stock can influence funding, and funding affects QMS maturity and resource availability." } }, { "@type": "Question", "name": "Can preferred stock influence a company's quality management system?", "acceptedAnswer": { "@type": "Answer", "text": "Yes, indirectly. Preferred stock provisions that affect company governance, funding, or management stability can impact the resources allocated to maintaining and improving the quality management system, as outlined in standards like ISO 13485:2016 clause 5.1." } }, { "@type": "Question", "name": "Are there any specific regulatory reporting requirements related to preferred stock?", "acceptedAnswer": { "@type": "Answer", "text": "While preferred stock itself isn't a direct reporting item for MedTech regulators, significant changes in company ownership or control, potentially triggered by preferred stock provisions, might need to be reported to authorities like the FDA (e.g., changes to establishment registration information) or competent authorities under the EU MDR, as these can affect accountability and regulatory contacts." } } ] } ] } --- [ MedTech Terms The authoritative reference ](/) Browse Learn [Latest](/latest) About 1. [Home](/) 2. / 3. [Terms](/terms) 4. / 5. [Investment & Finance](/terms?cat=Investment%20%26%20Finance) 6. / 7. Preferred Stock [All terms](/terms) Investment & Finance [Startup Lifecycle](/ecosystems/startup-lifecycle) # Preferred Stock Class of equity with rights superior to common stock. Reviewed by [Christian Espinosa, Founder, Blue Goat Cyber](/authors/christian-espinosa) Last reviewed May 5, 2026 ## Definition Preferred stock is the security class issued to venture investors. It carries a [liquidation preference](/terms/liquidation-preference), [anti-dilution protection](/terms/anti-dilution), dividend rights, protective provisions (veto rights over key actions), and often board representation - rights not held by common stockholders. What the regulation says While preferred stock itself is not directly regulated by MedTech-specific authorities, its implications for company ownership and control can indirectly affect regulatory compliance, particularly regarding accountability for quality management systems and reporting requirements. For instance, changes in company control due to preferred stock provisions might impact the designated " [person responsible for regulatory compliance](/terms/prrc)" under EU [MDR](/terms/mdr-reporting) (Article 15) or the " [management representative](/terms/management-representative)" described in 21 CFR 820.20(b)(3). ## What this means in practice Each round (Series Seed, A, B, C…) typically issues a new series of preferred with its own preference and rights, stacked in reverse order of issuance. ## Examples - A MedTech startup's Series B preferred stockholders use their veto rights to block an acquisition offer, thereby prolonging the time before the company has sufficient resources to upgrade its outdated quality management software to comply with 21 CFR Part 11. - A company's preferred stock agreement includes a provision that requires unanimous board approval for any major capital expenditure, delaying the purchase of a new manufacturing line needed to meet increased demand for a life-saving device and maintain production quality. - During a product recall, preferred stockholders exercise their protective provisions to delay public communication, conflicting with the urgent reporting requirements mandated by regulatory bodies like the FDA under 21 CFR 806. Common pitfalls - • A common pitfall is overlooking how preferred stock provisions granting veto rights can delay or complicate critical regulatory decisions, such as product recalls or significant quality system changes. - • Companies sometimes fail to communicate changes in ownership or control stemming from preferred stock agreements to regulatory bodies, which can be a reporting requirement in some jurisdictions. - • Misunderstanding the impact of liquidation preferences on a company's financial stability can indirectly affect its ability to maintain a robust quality management system and ensure product safety. - • Ignoring the potential for preferred stockholder influence to conflict with the independence required for certain regulatory roles, such as internal auditors or quality managers, is another mistake. ## Frequently asked questions How does preferred stock impact a MedTech company's regulatory obligations? Preferred stock provisions, particularly those granting control or veto rights, can influence a company's decision-making processes, which in turn affect its ability to meet regulatory deadlines, implement corrective actions, or respond to regulatory inquiries. It indirectly affects the regulatory obligations of a MedTech company as the distribution and terms of preferred stock can influence funding, and funding affects QMS maturity and resource availability. Can preferred stock influence a company's quality management system? Are there any specific regulatory reporting requirements related to preferred stock? ## Cross-references ### Part of A larger framework or document this term belongs to. - [ Term Sheet ](/terms/term-sheet) ## Related terms Grouped by theme ### Editor's picks · Hand-selected related concepts [ Investment & Finance Liquidation Preference Right of preferred shareholders to be paid before common in an exit. ](/terms/liquidation-preference) ### More in Investment & Finance · Same category [ Investment & Finance 409A Valuation An independent fair-market-value appraisal of common stock used to set tax-compliant strike prices for employee stock options. ](/terms/409a-valuation)[ Investment & Finance Anti-Dilution Protection Adjustment that protects investors if the company raises a future round at a lower price. ](/terms/anti-dilution)[ Investment & Finance Bridge Round Interim financing between priced rounds, usually convertible. ](/terms/bridge-round)[ Investment & Finance Burn Rate Rate at which a company spends cash, typically expressed monthly. ](/terms/burn-rate) Cited by Where this term appears across MedTech Terms. Ecosystems (1) - [Startup Lifecycle](/ecosystems/startup-lifecycle) ## Primary references 3 sources Link health: 3 verified · last checked 2026-06-20 NVCA· 1 SVB· 1 PitchBook· 1 1. [1 NVCA model docs Verified NVCA · nvca.org ](https://nvca.org/model-legal-documents/) 2. [2 Silicon Valley Bank - Healthcare Reports Verified SVB · svb.com ](https://www.svb.com/trends-insights/) 3. [3 PitchBook - MedTech Coverage Verified PitchBook · pitchbook.com ](https://pitchbook.com/news/articles/topic/healthtech) Inline markers like \[1\] jump to the matching reference above. Sponsor note ### Diligencing a MedTech cybersecurity posture? Blue Goat Cyber supports investors and acquirers with cybersecurity diligence on connected MedTech assets. [Book a 30-minute discovery session](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session) - No obligation - Expert-led from minute one - NDA available on request MedTech Terms is a community resource sponsored by [Blue Goat Cyber](https://bluegoatcyber.com). Definitions are independent of any vendor. On this term Category Investment & Finance Sources 3 Updated 5/5/2026 [Compare with another term](/compare?a=preferred-stock) Learn in 60 seconds Card Lesson Quiz Class of equity with rights superior to common stock. - · Each round (Series Seed, A, B, C…) typically issues a new series of preferred with its own preference and rights, stacked in reverse order of issuance. Remember this Watch out: A common pitfall is overlooking how preferred stock provisions granting veto rights can delay or complicate critical regulatory decisions, such as product recalls or significant quality system changes. Related terms - [Liquidation Preference ](/terms/liquidation-preference) You may also need Auto-suggested from Investment & Finance and shared keywords. - [Series A / B / C Financing Rounds ](/terms/series-funding) - [Anti-Dilution Protection ](/terms/anti-dilution) - [Term Sheet ](/terms/term-sheet) - [Drag-Along and Tag-Along Rights ](/terms/drag-tag-along) - [Liquidity Event ](/terms/liquidity-event) - [Convertible Note ](/terms/convertible-note) [All Investment & Finance terms](/terms?cat=Investment%20%26%20Finance) MedTech Terms An authoritative, plain-language reference for the regulatory, quality, cybersecurity, and software terms that shape modern medical devices. Browse - [All terms](/terms) - [A–Z index](/a-z) - [Categories](/categories) - [Ecosystems](/ecosystems) - [Learning paths](/paths) - [Compare terms](/compare) - [Quiz](/quiz) Resources - [FDA Medical Devices](https://www.fda.gov/medical-devices) - [EU MDR](https://eur-lex.europa.eu/eli/reg/2017/745/oj) - [IMDRF](https://www.imdrf.org/) - [Methodology](/methodology) - [Changelog](/changelog) - [Editor: Christian Espinosa](/authors/christian-espinosa) - [About this site](/about) © 2026 MedTech Terms. Reference content for educational purposes - not regulatory advice. A community resource sponsored by [Blue Goat Cyber](https://bluegoatcyber.com)